跳至主要内容
临床试验/PACTR202010738538062
PACTR202010738538062已完成未知

COMPARISON OF INTRAVENOUS LABETALOL AND HYDRALAZINE FOR THE CONTROL OF SEVERE HYPERTENSION IN PREGNANCY: A RANDOMIZED CONTROLLED TRIA

MUHAMMAD Sagir0 个研究点目标入组 120 人开始时间: 2020年9月30日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
Female

入选标准

  • Consenting pregnant women with severe hypertension in pregnancy with systolic blood pressure (SBP) of at least 160 mmHg and/or diastolic blood pressure (DBP) of at least 110 mmHg.
  • Gestational age of 28 weeks or more which will be determined based on ultrasound scan or last menstrual period.
  • Live singleton fetus with normal fetal heart rate.

排除标准

  • All women with cardiac disease such as heart block, ischaemic heart disease, and hypertensive cardiac disease.
  • History of allergy to either hydralazine or labetalol.
  • Chronic medical disorder such as chronic kidney disease and diabetes mellitus.
  • Women with haemoglobinopathy such as HbSS.
  • Multiple gestation.
  • Preterm labour at gestational age of less than 34 weeks
  • Women who are already on other antihypertensive drugs.
  • Patients with stroke
  • Unconscious patients
  • Patients with HELLP syndrome and liver disease
  • Presence of fetal distress
  • Non consenting women

研究者

发起方
MUHAMMAD Sagir

相似试验